More News

FDA okays IND application for familial adenomatous polyposis drug

Jim Cornall -
Sapience Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted the company an Investigational...

NTDpedia launched to fight neglected tropical diseases

Jim Cornall -
The Global Health Innovative Technology (GHIT) Fund has launched NTDpedia: Your Guide to Neglected Tropical Diseases. Designed as an accessible,...

Base to Base biotech podcast 76: Early disease detection and beating CNS cancers

Jim Cornall -
This week, we have conversations with Marc Hedrick, CEO of Cerenome, about a combined approach to tackling central nervous...

‘Positive trends’ from phase 2 amyotrophic lateral sclerosis trial

Jim Cornall -
Axoltis Pharma has announced topline results of SEALS, its phase 2 clinical trial evaluating the effect of NX210c in...

Successful results from trial of first-in-class Parkinson’s disease peptide

Jim Cornall -
Teitur Trophics, a biotechnology company developing novel neuroprotective peptides for neurodegenerative diseases, has announced successful results from its phase...

Researchers uncover how neurons deliver RNA where it is needed

Jim Cornall -
KAIST says a research team led by Ki-Jun Yoon of the Department of Biological Sciences has identified a mechanism...

Revvity to acquire Human Cell Design

Jim Cornall -
Revvity, Inc. has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specialising...

Engineered immune cells trial to fight colorectal cancer approved

Jim Cornall -
The U.S. Food and Drug Administration has granted permission for investigators at the University of Colorado Anschutz to conduct...

Elix and Axcelead DDP to collaborate on targeted protein degrader discovery

Jim Cornall -
Elix, Inc. and Axcelead Drug Discovery Partners, Inc. have entered into a collaborative research agreement aimed at the discovery...

Lotus Neuro launches to deliver therapies across blood-brain barrier

Jim Cornall -
Lotus Neuro, a clinical-stage biotechnology company pairing focused ultrasound with leading therapeutic modalities to treat focal neurologic disease, has...

Antibody targeting TSLP achieves positive results in asthma study

Jim Cornall -
Harbour BioMed has announced that its partner, Windward Bio, has reported positive interim results from the phase 2 portion...

Clinical trial shows knee osteoarthritis pain improvement

Jim Cornall -
Allegro NV, a Belgian biomedical company developing a nanotechnology treatment for osteoarthritis, has announced statistically significant improvements in pain...

Preclinical paper on CD73 small molecule inhibitor

Jim Cornall -
Antengene Corporation Limited has announced that a preclinical research paper evaluating the combination of ATG-037 (CD73 small molecule inhibitor)...

Positive results from relapsed/refractory B-cell lymphoma trial

Jim Cornall -
PeproMene Bio, Inc. has announced the publication in The Lancet of results from its phase 1 clinical trial evaluating...

EpilepsyGTx and Viralgen collaborating on AAV gene therapy epilepsy programme

Jim Cornall -
EpilepsyGTx, a biotechnology company developing gene therapies for refractory epilepsy, and Viralgen, a contract development and manufacturing organisation (CDMO)...

Base to Base biotech podcast 75: AI-powered diagnostics and cancer immunotherapy

Jim Cornall -
This week, we talk to a company in Lund, Asgard Therapeutics, and its co-founder and CEO Cristiana Pires, about...

Is atherosclerosis an autoimmune disease?

Jim Cornall -
A new study in mice and patients has led to a claim that atherosclerosis meets the criteria for an...

Northway Biotech opens €61m cell therapy and personalised medicine CDMO in Lithuania

Jim Cornall -
The first dedicated cell therapy and personalised medicine centre of its kind in the Baltic states has opened in...

Eascra Biotech receives NASA contract for space-manufactured nanomedicine

Jim Cornall -
Eascra Biotech, a nanomedicine startup with a lab in Worcester, Mass., has been awarded a NASA In Space Production...

Typewriter Therapeutics emerges from stealth with $56m to pursue in vivo CAR T medicines

Jim Cornall -
Typewriter Therapeutics, Inc. has emerged from stealth with $56m in Series A financing. Typewriter is a biotech company developing safe,...

Zifo says CMC bottleneck choking drug pipeline

Jim Cornall -
The biopharma industry has invested heavily in accelerating discovery. AI, machine learning (ML), high-throughput experimentation and advanced modelling are...